<p>根据最近向证券交易委员会（SEC）披露的信息，Dynamic Advisor Solutions LLC 在 2023 年第三季度将其在礼来公司的持股增加了 54.8%（NYSE:LLY - 免费报告）。该公司在本季度额外购买了 4,692 股后，持有 13,261 股礼来公司的股票。根据其最近向证券交易委员会（SEC）提交的文件，Dynamic Advisor Solutions LLC 在礼来公司的持股价值为 10,118,000 美元。</p>
<ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
<p>其他几家对冲基金也增加或减少了在 LLY 的持股。Chapin Davis Inc.在第三季度将其在礼来公司的持股增加了 13.3%。Chapin Davis Inc.现在拥有 2,222 股礼来公司的股票，价值为 1,695,000 美元，此前在该期间内额外购买了 261 股。Whalen Wealth Management Inc.在第三季度将其在礼来公司的股份增加了 758.9%。Whalen Wealth Management Inc.现在拥有 2,551 股礼来公司的股票，价值为 1,947,000 美元，此前在上个季度额外购买了 2,254 股。Riversedge Advisors LLC 在第三季度将其在礼来公司的持股增加了 61.1%。Riversedge Advisors LLC 现在拥有 472 股礼来公司的股票，价值为 360,000 美元，此前在上个季度额外购买了 179 股。MFG Wealth Management Inc.在第三季度将其在礼来公司的持股增加了 44.0%。MFG Wealth Management Inc.现在拥有 3,020 股礼来公司的股票，价值为 2,304,000 美元，此前在该期间内额外购买了 923 股。最后，Sheets Smith Investment Management 在第三季度购买了价值约 908,000 美元的礼来公司新股份。目前，82.53% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<h2>分析师升级和降级</h2>
<p>多家券商最近对 LLY 发布了报告。Erste Group Bank 在 10 月 14 日的研究报告中将礼来公司的评级从 “持有” 上调至 “买入”。美国银行在 12 月 15 日的研究报告中将礼来公司的股票目标价从 1,286.00 美元下调至 1,268.00 美元，并对该股票设定了 “买入” 评级。Sanford C. Bernstein 在周五的研究报告中重申了对礼来公司股票的 “跑赢大盘” 评级。大和资本市场在周二对礼来公司的股票设定了 1,230.00 美元的目标价，并给予该股票 “买入” 评级。最后，Leerink Partners 在周四的报告中重申了对礼来公司股票的 “跑赢大盘” 评级。四位股票研究分析师对该股票给予了强烈买入评级，十七位分析师给予了买入评级，五位分析师给予了持有评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 1,141.73 美元。</p>
<ul>
<li>辉瑞增加对减肥药物的重大投资</li>
</ul>
<p><strong>阅读我们最新的 LLY 股票分析</strong></p>
<h2>礼来公司新闻汇总</h2>
<p>以下是本周影响礼来公司的关键新闻：</p>
<ul>
<li>积极情绪：晚期试验胜利——礼来的口服 GLP-1 药物 orforglipron 在 ATTAIN-MAINTAIN III 期试验中达到了主要和所有关键的次要终点，显示从 Wegovy 或 Zepbound 转换的患者几乎保持了所有之前的体重减轻；礼来已向 FDA 提交了 orforglipron 用于肥胖症的申请。PR Newswire：礼来的 orforglipron 帮助人们维持体重减轻</li>
<li>积极情绪：项目势头和监管进展——中外药业和其他发布强调了积极的 III 期顶线结果以及礼来对 orforglipron 的 FDA 申请，强化了该公司在口服 GLP-1 领域的领导地位。如果获得批准，这将提高快速商业化的前景。TipRanks：中外药业强调积极的 III 期结果</li>
<li>积极情绪：分析师升级和上行预测——美国银行和其他机构指出了改善的质量指标，并预测了实质性的上行空间（美国银行提到新口服肥胖疗法的潜在数十亿美元销售），同时大和对 LLY 进行了升级——所有这些都支持更高的估值。Benzinga：美国银行看到股票上行空间 American Banking News：大和升级</li>
<li>中性情绪：管道深度——礼来将 eloralintide 推进至 III 期，增强了其在肥胖/糖尿病领域的管道，超越了 orforglipron；这对长期增长具有战略意义，但不是立即的收入驱动因素。TipRanks：礼来将 eloralintide 推进至 III 期</li>
<li>中性情绪：品牌/营销举措——礼来的消费者宣传（例如，奥运会相关活动）支持新疗法的认知，但对短期财务影响不明确。MM&amp;M：礼来推出了以美国队为主题的视频</li>
<li>消极情绪：加拿大的价格压力——路透社报道，礼来在加拿大将 Mounjaro 和 Zepbound 的价格下调了约 20% 或更多，这可能会压缩利润率或减少在面临更严格定价/监管审查的市场中每个处方的实际收入。路透社：礼来在加拿大降低糖尿病和减肥药物的价格</li>
</ul>
<h2>礼来公司股票表现</h2>
<ul>
<li>黄金交叉警报：3 只具有重大上行潜力的股票</li>
</ul>
<p>NYSE:LLY 周五开盘价为 1,071.35 美元。该公司的 50 日移动平均线为 960.76 美元，200 日移动平均线为 830.36 美元。该公司的市值为 1.01 万亿美元，市盈率为 52.41，市盈增长比率为 1.33，贝塔值为 0.37。该公司的速动比率为 1.24，流动比率为 1.55，债务与股本比率为 1.71。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日（星期四）发布了其财报。该公司报告本季度每股收益（EPS）为 7.02 美元，超出市场共识预期的 6.42 美元，超过 0.60 美元。该季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。礼来公司的收入同比增长了 53.9%。在去年同期，该公司每股收益为 1.18 美元。礼来公司已将 2025 财年的指引设定为每股收益 23.000-23.700。整体来看，卖方分析师预计礼来公司本年度将发布 23.48 的每股收益。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 3 月 10 日（星期二）支付。记录在案的股东将在 2 月 13 日（星期五）获得 1.73 美元的股息。除息日期为 2 月 13 日（星期五）。这相当于年化股息 6.92 美元，股息收益率为 0.6%。这比礼来公司之前的季度股息 1.50 美元有所增加。礼来公司的股息支付比率（DPR）为 29.35%。</p>
<h2>关于礼来公司</h2>
<p>（免费报告）</p>
<p>礼来公司（NYSE: LLY）是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>耐克在收益上超预期，但在中国面临困难并遭遇关税</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>人工智能热潮是泡沫吗？这两只股息股票说不是</li>
<li>什么是微型股？你需要知道的一切</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
<p>在你考虑投资礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Dynamic Advisor Solutions LLC 在第三季度将其在礼来的股份增加了 54.8%，目前持有 13,261 股，价值 1,010 万美元。其他公司也调整了他们的持仓。分析师们给予了积极的评级，普遍认为为 “适度买入”，目标价格为 1,141.73 美元。礼来的口服 GLP-1 药物 orforglipron 显示出积极的试验结果，提升了 FDA 批准和商业采用的前景</p>

<p>Dynamic Advisor Solutions LLC increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 54.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,261 shares of the company's stock after buying an additional 4,692 shares during the quarter. Dynamic Advisor Solutions LLC's holdings in Eli Lilly and Company were worth $10,118,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>根据最近向证券交易委员会（SEC）披露的信息，Dynamic Advisor Solutions LLC 在 2023 年第三季度将其在礼来公司的持股增加了 54.8%（NYSE:LLY - 免费报告）。该公司在本季度额外购买了 4,692 股后，持有 13,261 股礼来公司的股票。根据其最近向证券交易委员会（SEC）提交的文件，Dynamic Advisor Solutions LLC 在礼来公司的持股价值为 10,118,000 美元。</p>
</div><ul>
<li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li>
</ul>
<div class="lb-trans"><ul>
<li>三家医疗巨头刚刚提高了股息——看看谁支付得最多</li>
</ul>
</div><p>Several other hedge funds have also added to or reduced their stakes in LLY. Chapin Davis Inc. increased its position in Eli Lilly and Company by 13.3% in the 3rd quarter. Chapin Davis Inc. now owns 2,222 shares of the company's stock valued at $1,695,000 after acquiring an additional 261 shares during the period. Whalen Wealth Management Inc. grew its stake in shares of Eli Lilly and Company by 758.9% in the third quarter. Whalen Wealth Management Inc. now owns 2,551 shares of the company's stock worth $1,947,000 after purchasing an additional 2,254 shares during the last quarter. Riversedge Advisors LLC raised its position in Eli Lilly and Company by 61.1% during the 3rd quarter. Riversedge Advisors LLC now owns 472 shares of the company's stock worth $360,000 after purchasing an additional 179 shares during the last quarter. MFG Wealth Management Inc. lifted its holdings in Eli Lilly and Company by 44.0% during the 3rd quarter. MFG Wealth Management Inc. now owns 3,020 shares of the company's stock worth $2,304,000 after buying an additional 923 shares during the period. Finally, Sheets Smith Investment Management bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at about $908,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家对冲基金也增加或减少了在 LLY 的持股。Chapin Davis Inc.在第三季度将其在礼来公司的持股增加了 13.3%。Chapin Davis Inc.现在拥有 2,222 股礼来公司的股票，价值为 1,695,000 美元，此前在该期间内额外购买了 261 股。Whalen Wealth Management Inc.在第三季度将其在礼来公司的股份增加了 758.9%。Whalen Wealth Management Inc.现在拥有 2,551 股礼来公司的股票，价值为 1,947,000 美元，此前在上个季度额外购买了 2,254 股。Riversedge Advisors LLC 在第三季度将其在礼来公司的持股增加了 61.1%。Riversedge Advisors LLC 现在拥有 472 股礼来公司的股票，价值为 360,000 美元，此前在上个季度额外购买了 179 股。MFG Wealth Management Inc.在第三季度将其在礼来公司的持股增加了 44.0%。MFG Wealth Management Inc.现在拥有 3,020 股礼来公司的股票，价值为 2,304,000 美元，此前在该期间内额外购买了 923 股。最后，Sheets Smith Investment Management 在第三季度购买了价值约 908,000 美元的礼来公司新股份。目前，82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>A number of brokerages have recently issued reports on LLY. Erste Group Bank upgraded Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Tuesday, October 14th. Bank of America dropped their price target on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, December 15th. Sanford C. Bernstein reaffirmed an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a research note on Friday. Daiwa Capital Markets set a $1,230.00 price objective on shares of Eli Lilly and Company and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Finally, Leerink Partners restated an &#34;outperform&#34; rating on shares of Eli Lilly and Company in a report on Thursday. Four equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $1,141.73.</p>
<div class="lb-trans"><p>多家券商最近对 LLY 发布了报告。Erste Group Bank 在 10 月 14 日的研究报告中将礼来公司的评级从 “持有” 上调至 “买入”。美国银行在 12 月 15 日的研究报告中将礼来公司的股票目标价从 1,286.00 美元下调至 1,268.00 美元，并对该股票设定了 “买入” 评级。Sanford C. Bernstein 在周五的研究报告中重申了对礼来公司股票的 “跑赢大盘” 评级。大和资本市场在周二对礼来公司的股票设定了 1,230.00 美元的目标价，并给予该股票 “买入” 评级。最后，Leerink Partners 在周四的报告中重申了对礼来公司股票的 “跑赢大盘” 评级。四位股票研究分析师对该股票给予了强烈买入评级，十七位分析师给予了买入评级，五位分析师给予了持有评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “适度买入”，共识目标价为 1,141.73 美元。</p>
</div><ul>
<li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞增加对减肥药物的重大投资</li>
</ul>
</div><p><strong>Read Our Latest Stock Analysis on LLY</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 LLY 股票分析</strong></p>
</div><h2>Eli Lilly and Company News Roundup</h2>
<div class="lb-trans"><h2>礼来公司新闻汇总</h2>
</div><p>Here are the key news stories impacting Eli Lilly and Company this week:</p>
<div class="lb-trans"><p>以下是本周影响礼来公司的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Late‑stage trial win — Lilly’s oral GLP‑1 pill orforglipron met the primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial, showing patients who switched from Wegovy or Zepbound kept essentially all prior weight loss; Lilly has submitted orforglipron to the FDA for obesity. PR Newswire: Lilly's orforglipron helped people maintain weight loss</li>
<li>Positive Sentiment: Program momentum and regulatory progress — Chugai and other releases highlight positive topline Phase 3 results and Lilly’s FDA filing for orforglipron, reinforcing the company’s leadership in oral GLP‑1s. This raises prospects for rapid commercial adoption if approved. TipRanks: Chugai highlights positive Phase 3 results</li>
<li>Positive Sentiment: Analyst upgrades and upside forecasts — Bank of America and other outlets point to improved quality metrics and forecast material upside (BofA cites potential multi‑billion sales for new oral obesity therapies), while Daiwa upgraded LLY — all supportive of higher valuations. Benzinga: BofA sees room for stock upsideAmerican Banking News: Daiwa upgrade</li>
<li>Neutral Sentiment: Pipeline depth — Lilly advanced eloralintide into Phase 3, strengthening its obesity/diabetes pipeline beyond orforglipron; this is strategic for longer‑term growth but not an immediate revenue driver. TipRanks: Lilly advances eloralintide into Phase 3</li>
<li>Neutral Sentiment: Branding/marketing initiatives — Lilly’s consumer outreach (e.g., Olympics tie‑ins) supports awareness for new therapies but has unclear near‑term financial impact. MM&amp;M: Lilly debuts video featuring Team USA</li>
<li>Negative Sentiment: Pricing pressure in Canada — Reuters reported Lilly cut prices of Mounjaro and Zepbound in Canada by ~20% or more, which could compress margins or reduce realized revenue per prescription in markets facing tougher pricing/regulatory scrutiny. Reuters: Lilly cuts price of diabetes, weight-loss drugs in Canada</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：晚期试验胜利——礼来的口服 GLP-1 药物 orforglipron 在 ATTAIN-MAINTAIN III 期试验中达到了主要和所有关键的次要终点，显示从 Wegovy 或 Zepbound 转换的患者几乎保持了所有之前的体重减轻；礼来已向 FDA 提交了 orforglipron 用于肥胖症的申请。PR Newswire：礼来的 orforglipron 帮助人们维持体重减轻</li>
<li>积极情绪：项目势头和监管进展——中外药业和其他发布强调了积极的 III 期顶线结果以及礼来对 orforglipron 的 FDA 申请，强化了该公司在口服 GLP-1 领域的领导地位。如果获得批准，这将提高快速商业化的前景。TipRanks：中外药业强调积极的 III 期结果</li>
<li>积极情绪：分析师升级和上行预测——美国银行和其他机构指出了改善的质量指标，并预测了实质性的上行空间（美国银行提到新口服肥胖疗法的潜在数十亿美元销售），同时大和对 LLY 进行了升级——所有这些都支持更高的估值。Benzinga：美国银行看到股票上行空间 American Banking News：大和升级</li>
<li>中性情绪：管道深度——礼来将 eloralintide 推进至 III 期，增强了其在肥胖/糖尿病领域的管道，超越了 orforglipron；这对长期增长具有战略意义，但不是立即的收入驱动因素。TipRanks：礼来将 eloralintide 推进至 III 期</li>
<li>中性情绪：品牌/营销举措——礼来的消费者宣传（例如，奥运会相关活动）支持新疗法的认知，但对短期财务影响不明确。MM&amp;M：礼来推出了以美国队为主题的视频</li>
<li>消极情绪：加拿大的价格压力——路透社报道，礼来在加拿大将 Mounjaro 和 Zepbound 的价格下调了约 20% 或更多，这可能会压缩利润率或减少在面临更严格定价/监管审查的市场中每个处方的实际收入。路透社：礼来在加拿大降低糖尿病和减肥药物的价格</li>
</ul>
</div><h2>Eli Lilly and Company Stock Performance</h2>
<div class="lb-trans"><h2>礼来公司股票表现</h2>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上行潜力的股票</li>
</ul>
</div><p>NYSE:LLY opened at $1,071.35 on Friday. The company has a fifty day moving average of $960.76 and a 200-day moving average of $830.36. The firm has a market capitalization of $1.01 trillion, a P/E ratio of 52.41, a P/E/G ratio of 1.33 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99.</p>
<div class="lb-trans"><p>NYSE:LLY 周五开盘价为 1,071.35 美元。该公司的 50 日移动平均线为 960.76 美元，200 日移动平均线为 830.36 美元。该公司的市值为 1.01 万亿美元，市盈率为 52.41，市盈增长比率为 1.33，贝塔值为 0.37。该公司的速动比率为 1.24，流动比率为 1.55，债务与股本比率为 1.71。礼来公司的 12 个月低点为 623.78 美元，12 个月高点为 1,111.99 美元。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company's revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 10 月 30 日（星期四）发布了其财报。该公司报告本季度每股收益（EPS）为 7.02 美元，超出市场共识预期的 6.42 美元，超过 0.60 美元。该季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。礼来公司的收入同比增长了 53.9%。在去年同期，该公司每股收益为 1.18 美元。礼来公司已将 2025 财年的指引设定为每股收益 23.000-23.700。整体来看，卖方分析师预计礼来公司本年度将发布 23.48 的每股收益。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio (DPR) is 29.35%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 3 月 10 日（星期二）支付。记录在案的股东将在 2 月 13 日（星期五）获得 1.73 美元的股息。除息日期为 2 月 13 日（星期五）。这相当于年化股息 6.92 美元，股息收益率为 0.6%。这比礼来公司之前的季度股息 1.50 美元有所增加。礼来公司的股息支付比率（DPR）为 29.35%。</p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司（NYSE: LLY）是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>What is a Microcap Stock? Everything You Need to Know</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>纳斯达克是什么？完整概述及历史</li>
<li>耐克在收益上超预期，但在中国面临困难并遭遇关税</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>人工智能热潮是泡沫吗？这两只股息股票说不是</li>
<li>什么是微型股？你需要知道的一切</li>
<li>2026 年四只高潜力 ETF：小型股、太空股票等</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Dynamic Advisor Solutions LLC 购买了 4,692 股礼来公司（Eli Lilly）的股票$LLY